# Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

> **NCT05753826** · PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Ovarian Neoplasms
- Ovarian Diseases

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Fuzuloparib

## Key facts

- **NCT ID:** NCT05753826
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753826, "Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05753826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*